Premium
Interleukin‐8 and RANTES levels in patients with relapsing–remitting multiple sclerosis (RR‐MS) treated with cladribine
Author(s) -
BartosikPsujek H.,
Belniak E.,
MitosekSzewczyk K.,
Dobosz B.,
Stelmasiak Z.
Publication year - 2004
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.2004.00259.x
Subject(s) - cladribine , multiple sclerosis , medicine , proinflammatory cytokine , immunology , relapsing remitting , cerebrospinal fluid , pathogenesis , chemokine , interleukin , cytokine , inflammation
Objective – Chemokines are involved in the pathogenesis of multiple sclerosis. The aim of the study was to evaluate the effects of immunosuppressive therapy on production of two proinflammatory chemokines – interleukin‐8 (IL‐8) and RANTES (regulated on activation, normal T cell expressed and secreted). Materials and methods – Twenty‐five patients with relapsing–remitting multiple sclerosis were treated with 2‐chlorodeoxyadenosine (Cladribine), administered subcutaneously in 6 cycles repeated every 5 weeks. IL‐8 and RANTES levels were measured by the enzyme‐linked immunoassay (ELISA) method in serum and cerebrospinal fluid (CSF) before and after treatment. Results – After Cladribine treatment the levels of IL‐8 decreased significantly in CSF only, whereas the RANTES levels decreased significantly both in CSF and serum. Conclusion – Our results suggest that Cladribine therapy might modify the circulating level of RANTES.